anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
According to the total population of cancer patients, hepatocellular carcinoma (HCC) and colorectal cancer (CRC), two of gastroenterological cancers are involved in the most acquired five cancers. Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, and HCC is one of the top ten cancers in China. Currently, the intervention for gastrointestinal cancers mainly focuses on surgical removal, but patients still have a high risk of recurrence. Thus, the prevention of cancer recurrence is the most crucial topic for the intervention. The pathophysiology of gastroenterological cancers is multifactorial and not yet completely understood. However, immunosuppression is a major contributing factor in tumor cells play a central part in disease progression. It determines the prognosis of patients.

The immune checkpoint or complementary therapy in the course of cancer treatment has been reported as effective methods for patients. In recent years, more integrated treatment studies have found that acupuncture can improve the discomfort and pain caused by chemotherapy. In addition, the treatment of rheumatoid arthritis has shown that acupuncture can effectively regulate the immunity of patients. In this study, investigators are considering to apply modern acupuncture as the immune modulation in gastroenterological cancers. Modern acupuncture is to use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers. The infiltration of a specific subtype of T-cell and the expression of PD-L1 in tumors may be applied as indicators of cancer prognosis. These CD8 T cells (also called Tex cells) often fail to eradicate tumors and can become dysfunctional or exhausted. The magnitude of the reinvigoration of circulating Tex cells determined in relation to pretreatment tumor burden correlated with clinical response. By monitoring Tex cells, investigators will evaluate the feasibility of acupuncture as a complementary therapy to regulate the immune functions of patients with gastroenterological cancers
Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
Miltefosine will be administered per os at 150 mg/day \[50 mg tid\] for 28 days. This is the standard regimen of miltefosine for persons \>45 kg.
Binarized convolutional neural networks (bCNNs) are favored for the design of low-storage, low-power cardiac arrhythmia classifiers owing to their high weight compression rate. However, multi-class classification of ECG signals based on bCNNs is challenging due to the accuracy loss introduced by the binarization operation. In this paper, an effective multi-classifier system is proposed for electrocardiogram (ECG) signals using a binarized depthwise separable convolutional neural network (bDSCNN) with the merged convolution-pooling (MCP) method. The binarized depthwise separable convolution layer is adopted to reduce the increased number of parameters in multi-classification systems. Instead of operating convolution and pooling sequentially as in a traditional convolutional neural network (CNN), the MCP method merges pooling together with convolution layers to reduce the number of computations. To further reduce hardware resources, this work employs blockwise incremental calculation to eliminate redundant storage with computations. In addition, the R peak interval data are integrated with P-QRS-T features to improve the classification accuracy. The proposed bDSCNN model is evaluated on an Intel DE1-SoC field-programmable gate array (FPGA), and the experimental results demonstrate that the proposed system achieves a five-class classification accuracy of 96.61% and a macro-F1 score of 89.08%, along with a dynamic power dissipation of 20 μW for five-category ECG signal classification. The hardware resource usage of BRAM and LUTs plus REGs is reduced by at least 2.94 and 1.74 times, respectively, compared with existing ECG classifiers using bCNN methods.
A system is disclosed for generating patient-related medical information. The system includes a healthcare provider transformer application that automatically converts patient medical information into a language suitable for sharing with various individuals involved in a patient's care. The healthcare transformer application receives medical data inputted by a healthcare provider and identifies key medical terms and abbreviations from the inputted data. It then translates these key terms and abbreviations into pre-defined simple language definitions and generates a legible simple text by combining the definitions. The system further hybridizes the simple text by adding extra separators, formatting, additional text, general advice, disclaimer, date and time, logos, images, illustrations, tables, and machine- readable codes such as barcodes, QR codes, and encrypted codes. The system generates a hybrid output based on the hybridized text, which includes instructions that are both human readable and machine-readable.
Take guanfacine extended-release tablets orally once daily, either in the morning or evening, at approximately the same time each day. Begin at a dose of 1 mg/day, and adjust in increments of no more than 1 mg/week.

In monotherapy-clinical trials, there was dose- and exposure-related clinical improvement as well as risks for several clinically significant adverse reactions (hypotension, bradycardia, sedative events). To balance the exposure-related potential benefits and risks, the recommended target dose range depending on clinical response and tolerability for guanfacine extended-release is 0.05 to 0.12 mg/kg/day (total daily dose between 1 mg to   
4 mg). 

In the adjunctive trial which evaluated guanfacine extended-release treatment with psychostimulants, the majority of patients reached optimal doses in the 0.05 to 0.12 mg/kg/day range. Doses above 4 mg/day have not been studied in adjunctive trials.

Additional pediatric use information for patients ages 6 to 17 years is approved for Shire US Inc.’s INTUNIV® (guanfacine) extended-release tablet product. However, due to Shire US Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
It is intended to provide a scaffold whereby a bone and a metallic material can three-dimensionally form together a stereoscopic binding layer. Thus, a geometric space sufficient for cell actions is provided. As a result, the time required for the formation of a stereoscopic bond can be shortened and, moreover, a bond can be self-repaired owing to cell actions even in the case where a part of the bond is injured by a wound, etc. As a material for designing a scaffold, titanium fibers of less than 100 µm in size and having an aspect ratio of 20 or more are selected. Then these fibers are intertwisted together to form a layer. A space having an excellent ability to induce a biological hard tissue and fix the same is provided from the surface to the inside of the fiber layer and the resultant material is fixed to the periphery of an implant.
The invention discloses a bacillus licheniformis which is separated from eel intestinal tracts Bacillus licheniformis ) AJQ05 and its application. The strain is preserved in China Center for Type Culture Collection (CCTCC) in 2023, 7 and 25 days, and the preservation number is CCTCC NO: m20231382, the preservation address is No. 299 of Wuchang district of Wuhan, hubei province. Bacillus licheniformis AJQ has the capability of producing 4 extracellular enzymes; the tolerance is strong; the space locus competition is dominant, and when the space locus competition and the germ competition are adhered, the space locus competition and germ competition have higher adhesion inhibition rate; the traditional Chinese medicine composition is sensitive and moderately sensitive to 30 antibiotics common in the aquatic industry. Therefore, the strain can be applied to preparing aquatic animal feed additives and aquaculture water additives and can be applied to producing protease, amylase, lipase and cellulase. The bacillus licheniformis lays a foundation for accurately researching the biological characteristics of the bacillus licheniformis and defines the application range of the strain.
The invention belongs to the field of immunology, and relates to a humanized anti-CD 25 single-domain antibody and application thereof. The single domain antibody is composed of a heavy chain, the heavy chain comprises a heavy chain CDR1 shown in SEQ ID NO. 17, a heavy chain CDR2 shown in SEQ ID NO. 18 and a heavy chain CDR3 shown in SEQ ID NO. 19, and the heavy chain also comprises a framework region FR; the framework region FR includes amino acid sequences of FR1, FR2, FR3 and FR4, and the framework region FR sequence is humanized and modified. Compared with the prior art, the invention has the beneficial effects that: the anti-CD 25 single-domain antibody provided by the invention is subjected to humanized transformation, maintains the affinity and the tumor cell proliferation blocking effect, and effectively reduces the immune side reaction.
A total of 48 old adults will be enrolled, evaluated and trained. They will be randomly assigned to two groups: one exercise group (perturbation training) and one group without perturbation. No gender based differences are expected for the recovery outcome measures so we will be able to pool male and female individuals for this analysis. Each subject of the experimental and of the control groups will be trained on 24 occasions over a period of 10-12 weeks (20-30 minutes, 2-3 times/week). This regimen was based on previous balance training study that demonstrated improvements in balance control with similar training duration and frequency. Gait and balance function and physical activity level will be tested in both groups before, immediately after, 3 and 6 months after completion of the training period to explore the benefit and carryover of training. In addition using monthly phone calls, falls, their severity, functional activity limitations in the home and community setting and health status will be monitored 12 months after the training period.
For solid metastatic tumors, 30 patients will be recruited, which can be from the colon, pancreas, stomach, and bile ducts, divided into two groups of 15 patients, an intervention group and a placebo group. The intervention group will receive the Esperanza extract at DMT for three continuous treatment cycles (approximately 12 weeks), and the other group will receive the placebo.
For pregnant and postpartum women living with HIV (PPHIV) in resource-limited settings, maintaining retention in care and viral suppression, and preventing mother-to-child transmission of HIV, are major implementation challenges in the PMTCT cascade. The goal of this study is to execute and evaluate the implementation of a differentiated service delivery (DSD) model for PMTCT to address these challenges. Specifically, this is a pilot study that will evaluate the implementation of a DSD model for PMTCT in a resource-constrained setting in Kenya. The objective of the DSD model is to improve retention in care and viral suppression for PPHIV. In the DSD approach, clinical services are simplified and adapted to the needs and preferences of clients who are clinically stable, allowing the health system to provide intensified services to the clients who unstable according to their needs. Set clinical criteria will be used to determine which PPHIV and their HIV-exposed children are clinically stable and which are unstable. The DSD model will be implemented at Huruma Sub-District Hospital in western Kenya which offers integrated PMTCT services. Over a period of 12 months, all PPHIV that attend this clinic will be recruited to participate in the DSD model as part of the study. The clinical staff will be responsible for triaging PPHIV and their children as stable or unstable according to the DSD eligibility criteria. The implementation success of the DSD model will be determined using the RE-AIM implementation outcomes. This will involve semi-structured interviews with PPHIV and focus group discussions with PMTCT providers participating in the model. Time-motion analysis and medical record review will also be performed to better understand the implementation process and data needed in preparation a future implementation-effectiveness clinical trial. Commensurate with the scope of this pilot implementation study, participants will not be randomized and there will not be a required minimum sample size. The findings from this study will serve as a foundation for a future, large-scale trial to test the effectiveness and implementation of the DSD model for PMTCT in a resource-limited setting.
The present invention relates to pharmaceutical formulations comprising gaboxadol for therapeutic treatment. Pharmaceutical formulations comprising gaboxadol or a pharmaceutically acceptable salt thereof and methods of treating essential tremor, tourette's syndrome or fragile X syndrome are provided. The pharmaceutical formulations herein include transdermal formulations and modified release dosage forms. In embodiments, the modified release dosage form comprises an orally disintegrating dosage form. In embodiments, the modified release dosage form comprises an extended release dosage form. In embodiments, the modified release dosage form comprises a delayed release dosage form. In embodiments, the modified release dosage form comprises a pulsatile release dosage form.
PURPOSE: A lotion generator is provided to have skin conditioning and cosmetical advantages by spreading obtained alkaline water from the ionization using generated electric potential difference produced between a reacting agent with electromotive force and water. CONSTITUTION: A lotion generator comprises a container(10), reacting agents(50), a filtering layer(30), a spraying element(40), and an electromotive force enriching element(20) in a pyramidal shape. The container stores water through an entrance(12). The reacting agents are built inside of the container to comprise the ionization of water by the circulating electric potential action due to electromotive force. The filtering layer is installed on the upper part of the reacting agents within the container. The spraying element is connected to a discharging pipe(14) which discharges the water by spraying at the entrance of the container. The electromotive force enriching element in the pyramidal shape is stored in the container, and increases the electromotive force on the reacting agents by drawing the electric charges.
A method and system for improving the software programming of a robot system, comprising monitoring of plurality of human user-robot interactive pairs' (HURIP) interactions. System comprises each of said plurality of HURIPs as using 'front-end' semi-autonomous robot component linked by wireless two-way communications to a 'back-end' cloud-based computerized component. Monitoring comprises review of robot sensor-gathered data and data from camera and audio data from homes of users during user-robot interactions. Analysis of said monitoring by authorized observers such as psychologist, parent, teacher, system administrator, software programmer(s), enables identification of areas for software improvement. Improved software is tested, wherein testing comprises at least similar monitoring of HURIPs, and wherein said testing comprises social robots comprising said updated software. Cycles of such monitoring of HURIP interactions, analyzing data derived from said monitoring, focus for improvement derived thereof and followed-up in coding updates, testing of updates comprising use within monitored HURIP interactions, such cycles are applied in herein disclosed method to manufacture progressively improved code for and uses of social robot system.
INTRODUCTION: This study aimed to investigate whether regional cerebral perfusion patterns on early-phase 18F-FP-CIT PET scans, which is typically coupled to cerebral metabolism, predict the long-term prognosis of Parkinson's disease (PD).
METHODS: We enrolled 397 drug-naïve patients with early-stage PD who underwent dual-phase 18F-FP-CIT PET scans. After quantifying the early-phase 18F-FP-CIT PET images, cluster analysis was performed to delineate the PD subtypes according to the patterns of regional cerebral perfusion. We compared the risk of developing levodopa-induced dyskinesia (LID), wearing-off, freezing of gait (FOG), and dementia between the PD subtypes.
RESULTS: Cluster analysis classified patients into three subtypes: cluster 1 (relatively preserved cortical uptake; n = 175), cluster 2 (decreased uptake in the frontal, parietal, and temporal regions; n = 151), and cluster 3 (decreased uptake in more extensive regions, additionally involving the lateral occipital regions; n = 71). Cluster 1 was characterized by a younger age-of-onset, less severe motor deficits, less severely decreased 18F-FP-CIT binding in the caudate, and better cognitive performance. Cluster 3 was characterized by an older age-of-onset, more severe motor deficits, and poorer cognitive performance. Cluster 2 was intermediate between clusters 1 and 3. Cox regression analyses demonstrated that clusters 2 and 3 had a higher risk for dementia conversion than cluster 1, whereas the risk for developing LID, wearing-off, and FOG did not differ among the clusters.
CONCLUSION: The patterns of regional cerebral perfusion can provide information on long-term prognosis with regards to cognitive, but not motor aspects of patients with early-stage PD.
This is a multi-center, randomized, double-blind, placebo-controlled, single ascending dose phase Ib study in anemic stage 5 chronic kidney disease patients requiring hemodialysis. Eligible subjects will undergo screening assessments and PRS-080#22-DP will be administered by intravenous infusion. The study will consist of 3 dose cohorts of 2 mg/kg, 4 mg/kg, and 8 mg/kg body weight with 8 subjects in each cohort. Using a standard 6+2 design, 6 subjects in each cohort will be randomized to PRS-080#022-DP and 2 subjects in each cohort will be randomized to placebo. The decision to escalate the dose will be based on an interim analysis of clinical safety and safety laboratory data. Safety and tolerability, pharmacokinetics, pharmacodynamics as well as potential immunogenicity will be investigated.
Assessing the risk of postoperative cardiovascular events before performing non-cardiac surgery is clinically important. The current risk score systems for preoperative evaluation may not adequately represent a small subset of high-risk populations. Accordingly, this study aimed at applying iterative random forest to analyze combinations of factors that could potentially be clinically valuable in identifying these high-risk populations. To this end, we used the Japan Medical Data Center database, which includes claims data from Japan between January 2005 and April 2021, and employed iterative random forests to extract factor combinations that influence outcomes. The analysis demonstrated that a combination of a prior history of stroke and extremely low LDL-C levels was associated with a high non-cardiac postoperative risk. The incidence of major adverse cardiovascular events in the population characterized by the incidence of previous stroke and extremely low LDL-C levels was 15.43 events per 100 person-30 days [95% confidence interval, 6.66-30.41] in the test data. At this stage, the results only show correlation rather than causation; however, these findings may offer valuable insights for preoperative risk assessment in non-cardiac surgery.
PURPOSE: A composition containing Lactobacillus sp. HY7801 as an active ingredient is provided to suppress urinary tract infection and E.coli adhesion onto bladder epithelial cells. CONSTITUTION: Lactobacillus sp. HY7801 is capable of suppressing urinary tract infection and candida vaginitis. The Lactobacillus sp. HY7801 can suppress E.coli, Proteus vulgaris, Proteus mirabilis, Klebsiella oxytoca, Klebsiella pneumonia, Morganella morganii, Citrobacter freundii, Enterococcus fecalis, Enterobacter cloaca, Pseudomonas aeruginosa, or Acinetobacter banmanii. A pharmaceutical composition for preventing and treating urinary tract infection contains the Lactobaicllus sp. HY7801 as an active ingredient.
Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
A method is implemented by at least one server. The method includes obtaining a set of users as a function of profile records regarding a plurality of users. The method includes defining a subset of the users as a peer group based on peer group formation features by applying a clustering algorithm to profile records of the set of users. The method includes calculating a peer group metric value for the peer group based on behaviors of the subset of users in the peer group. The method includes calculating a user metric value for a target-user included in the subset based on behavior of the target-user. The method includes constructing a message relating the patient metric value to the peer group metric value.
Cellobio-oligosaccharides (CBO) produced by the dextransucrase-catalyzed transglycosylation reaction of sucrose and cellobiose were discovered to be effective as antifungal agents against dental caries and against fungi who rely on glucan as an integral part of the cell wall, e.g.,  A. terreus . The cellobio-oligosaccharides were found to be inhibitors of β-(1,3)-glucan synthase, an important enzyme involving in fungal cell wall component synthesis. The CBO caused structural changes in the growing fungal cells. In addition, the CBO were shown to be effective as anti-cariogenic agents in preventing bacterial adherence to teeth by inhibiting the formation of the bacterial plaque (glucans), e.g., that formed by  Streptococcus mutans . Cellobio-oligosaccharides produced by dextransucrase were analyzed and shown to have a degree of polymerization (DP) ranging from 3 to 6 glucosyl groups. Examples of these cellobio-oligosaccharides produced by this method include, but are not limited to, trisaccharides such as α-D-glucopyranosyl-(1→2)-β-D-glucopyranosyl-(1→4)-D-glucopyranose and α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl-(1→4)-D-glucopyranose.
One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
We plan to undertake a randomized controlled trial to evaluate the effectiveness of an office-based educational intervention for the prevention of iron depletion in young children. Healthy children will be recruited from a community pediatric office which serves a diverse, urban population. Children will be randomized to the intervention education group or the control education group at 9 months of age. Blood work (\~4mL) for complete blood count and ferritin along with additional measures such as transferrin, iron, and reticulocyte count will be obtained at 24 months of age. Rates of iron depletion and anemia will be compared in the two groups. The two groups will also have 25-hydroxy vitamin D, calcium and alkaline phosphatase levels analyzed at the 24 month visit to ensure that the intervention for prevention of iron depletion does not adversely affect these measures.